Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2097MR)

This product GTTS-WQ2097MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2097MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3650MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12085MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ964MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10715MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ10089MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ1033MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ1037MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ13089MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW